Categories
Prostate cancer

Should LHRH therapy be continued in patients receiving abiraterone acetate?

  • Ohlmann CH, Jäschke M, Jaehnig P, Krege S, Gschwend J, Rexer H, et al. LHRH sparing therapy in patients with chemotherapy-naïve, mCRPC treated with abiraterone acetate plus prednisone: results of the randomized phase II SPARE trial. Prostate Cancer Prostatic Dis. 2022. https://doi.org/10.1038/s41391-022-00533-6

  • Supiot S, Campion L, Pommier P, Dore M, Palpacuer C, Racadot S, et al. Combined abiraterone acetate plus prednisone, salvage prostate bed radiotherapy and LH-RH agonists (CARLHA-GEP12) in biochemically-relapsing prostate cancer patients following prostatectomy: A phase I study of the GETUG/GEP. Oncotarget. 2018;9:22147–22157. https://doi.org/10.18632/oncotarget.25189

    Article 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Maluf FC, Schutz FA, Cronemberger EH, Luz MA, Martins SPS, Muniz DQB, et al. A phase 2 randomized clinical trial of abiraterone plus ADT, apalutamide, or abiraterone and apalutamide in patients with advanced prostate cancer with non-castrate testosterone levels (LACOG 0415). Eur J Cancer. 2021;158:63–71. https://doi.org/10.1016/j.ejca.2021.08.032

    CAS 
    Article 
    PubMed 

    Google Scholar
     

  • Mariani S, Salvatori L, Basciani S, Arizzi M, Franco G, Petrangeli E, et al. Expression and cellular localization of follicle-stimulating hormone receptor in normal human prostate, benign prostatic hyperplasia and prostate cancer. J Urol. 2006;175:2072–7. https://doi.org/10.1016/S0022-5347(06)00273-4

    CAS 
    Article 
    PubMed 

    Google Scholar
     

  • Radu A, Pichon C, Camparo P, Antoine M, Allory Y, Couvelard A, et al. Expression of follicle-stimulating hormone receptor in tumor blood vessels. N Engl J Med. 2010;363:1621–30. https://doi.org/10.1056/NEJMoa1001283

    CAS 
    Article 
    PubMed 

    Google Scholar
     

  • Leave a Reply